Results 111 to 120 of about 18,928 (205)

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis

BMC Cardiovascular Disorders, 2018
Background Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied.
Pravesh Kumar Bundhun, Feng Huang
doaj   +1 more source

Access and non–access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events:Systematic review and meta-analysis [PDF]

, 2015
Background: The prognostic impact of site-specific major bleeding complications after percutaneous coronary intervention (PCI) has yielded conflicting data.
Buchan, Iain, de Belder, Mark A., Khan, Muhammad A., Kinnaird, Tim, Kwok, Chun Shing, Loke, Yoon K., Ludman, Peter F., Mamas, Mamas A, Nolan, James, Rao, Sunil V., Sperrin, Matt   +10 more
core   +1 more source

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention

Open Heart, 2019
Background There is a paucity of real-world outcome data comparing clopidogrel, prasugrel and ticagrelor in primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
Jim McLenachan, Christopher Malkin, Daniel J Blackman, John Greenwood, Stephen Wheatcroft, Paul Baxter, Arvindra Krishnamurthy, Claire Keeble, Michelle Anderson, Kathryn Somers, Natalie Burton-Wood, Charlotte Harland, Jonathan Blaxill   +12 more
doaj   +1 more source

Impact of Society Guidelines on Trends in Use of Newer P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Over the past decade, major society guidelines have recommended the use of newer P2Y12 inhibitors over clopidogrel for those undergoing percutaneous coronary intervention for acute coronary syndrome.
Mohamed O. Mohamed, Evangelos Kontopantelis, Mirvat Alasnag, Leila Abid, Amitava Banerjee, Andrew S. P. Sharp, Christos Bourantas, Alex Sirker, Nick Curzen, Mamas A. Mamas   +9 more
doaj   +1 more source

Investigação recente em antitrombóticos. Novidades para o tratamento dos doentes com síndromas coronárias agudas [PDF]

, 2010
A terapêutica antitrombótica ocupa um lugar central no tratamento da doença coronária aguda. A sua importância foi reforçada com a generalização dos procedimentos de intervenção percutânea, em especial quando são implantados dispositivos intra-coronários.
Morais, João
core  

Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock

Frontiers in Cardiovascular Medicine
BackgroundData are lacking on the effects of the alternation of P2Y12 receptor antagonists (P2Y12) on bleeding and outcome in patients with myocardial infarction (MI) with cardiogenic shock (CS). We compared the effects of different P2Y12 and alternation
Vojko Kanic, Gregor Kompara
doaj   +1 more source

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]

, 2019
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E., Bhatt, Deepak L., Jennings, Lisa K., Lee, John S., Mays, Michael C., Pollack, Charles V., Umstead, Bret R., Weitz, Jeffrey I., Xu, Sherry   +8 more
core   +1 more source

Prasugrel [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

In silico Investigation on Clopidogrel, Prasugrel and Ticagrelor as Potential Mono Antiplatelet Therapy for Acute Coronary Syndrome

MCBS (Molecular and Cellular Biomedical Sciences)
Background: In acute coronary syndrome (ACS), antiplatelet therapy is crucial for inhibiting platelet aggregation. Dual antiplatelet therapy (DAPT) commonly employs aspirin along with clopidogrel, prasugrel, or ticagrelor. This is well known that aspirin
Muhammad Naufal Hibatullah, Suryono Suryono, Sheilla Rachmania   +2 more
doaj   +1 more source

Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety

Medicines
Introduction: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. Purpose: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatelet ...
Fadel Bahouth, Boris Chutko, Haitham Sholy, Sabreen Hassanain, Gassan Zaid, Evgeny Radzishevsky, Ibrahem Fahmwai, Mahmod Hamoud, Nemer Samnia, Johad Khoury, Idit Dobrecky-Mery   +10 more
doaj   +1 more source